ProMIS licenses Ossianix brain-delivery technology for Alzheimer’s antibody

ProMIS Neurosciences has licensed Ossianix’s TXP1 technology to improve antibody delivery to the brain, initially targeting its Alzheimer’s disease programme.

ProMIS Neurosciences has licensed a brain-delivery technology from Ossianix to support development of its Alzheimer’s disease antibody PMN310, with options to extend the approach to its Parkinson’s disease and amyotrophic lateral sclerosis (ALS) programmes.

The agreement gives ProMIS rights to use TXP1, a technology targeting transferrin receptor 1 (TfR1), to transport therapeutic antibodies across the blood-brain barrier. The companies have not disclosed the financial terms, but Ossianix will receive an upfront payment, development, regulatory and commercial milestone payments, and royalties on global net sales.

The deal is intended to support a potential second-generation version of PMN310, which ProMIS believes could offer more convenient subcutaneous dosing and lower manufacturing costs.

PMN310 is designed to selectively target toxic amyloid-beta oligomers associated with Alzheimer’s disease. It is being evaluated in the PRECISE-AD randomised, placebo-controlled Phase 1b study in people with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease. The company says its ongoing development of PMN310 as an intravenous and subcutaneous product will continue independently of the TXP1 agreement.

Preclinical studies report increased brain delivery

TXP1 is based on a deimmunised, single-domain VNAR antibody scaffold, which is smaller than a conventional antibody. It binds to TfR1, a receptor involved in the transport of substances across the blood-brain barrier.

In preclinical studies conducted by Ossianix, including work in non-human primates, TXP1 increased delivery of a therapeutic antibody to the brain by more than 65-fold.

Ossianix also reported that the studies showed no accumulation in the liver, spleen, lungs, kidneys, bone marrow, heart or muscle. The technology was associated with prolonged brain exposure, binding that did not compete with transferrin, and minimal effects on reticulocyte levels. Changes in reticulocyte levels have been reported with some other TfR1-targeting approaches.

These findings are preclinical and have not established that TXP1 will improve antibody delivery or treatment outcomes in people. ProMIS also acknowledged that results from preclinical studies may not predict outcomes in later studies or clinical development.

Neil Warma, president and chief executive officer of ProMIS Neurosciences, said: “This partnership is in support of the long-term value of our pipeline. Our ongoing efforts with PMN310 are unaffected by this agreement and we remain committed to advancing it as an intravenous (IV) and subcutaneous product, subject to upcoming data.”

Options for Parkinson’s and ALS programmes

The licence also includes options for ProMIS to apply TXP1 to two other antibody programmes.

PMN442 targets alpha-synuclein, a protein implicated in Parkinson’s disease and dementia with Lewy bodies. PMN267 targets TDP-43, which is associated with ALS and frontotemporal dementia.

The potential to use the same delivery technology across several neurodegenerative disease programmes gives ProMIS an opportunity to explore its application beyond Alzheimer’s disease. However, the company has not confirmed that it will exercise either option.

Frank Walsh, CEO of Ossianix, said: “We are proud to partner with ProMIS and see this agreement as strong validation of TXP1’s profile as a next-generation TfR1-targeting delivery technology. By pairing our deimmunized VNAR platform—which binds a unique epitope—with ProMIS’s selective antibodies, we see a compelling opportunity to enable more convenient dosing across Alzheimer’s and expand into additional neurodegenerative programs.”

ProMIS said it expects to meet its short-term obligations under the agreement using existing cash resources and does not anticipate the deal changing its previously disclosed cash runway through 2027. The financial arrangements remain undisclosed.

The agreement adds a potential delivery strategy to ProMIS’s neurodegenerative disease pipeline, although its clinical value will depend on whether the preclinical findings translate into human studies.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox